A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)

[1]  J. Machiels,et al.  A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE) , 2019, Journal of Immunotherapy for Cancer.

[2]  P. Tran,et al.  Clinical Development of Novel Drug–Radiotherapy Combinations , 2018, Clinical Cancer Research.

[3]  T. Hothorn,et al.  Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Publisher's Note , 2018, Anaesthesia.

[5]  T. Hothorn,et al.  Tumor Regression Grading After Preoperative Chemoradiotherapy as a Prognostic Factor and Individual-Level Surrogate for Disease-Free Survival in Rectal Cancer , 2017, Journal of the National Cancer Institute.

[6]  R. Salazar,et al.  Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection , 2017, Journal of Immunotherapy for Cancer.

[7]  L. Seymour,et al.  Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization , 2017, Front. Oncol..

[8]  M. Mulcahy,et al.  Safety and tolerability of veliparib combined with capecitabine plus radiotherapy in patients with locally advanced rectal cancer: a phase 1b study. , 2017, The lancet. Gastroenterology & hepatology.

[9]  D. Joseph,et al.  Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04) , 2017, Annals of surgery.

[10]  D. Ferguson,et al.  Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators , 2016, Molecular therapy oncolytics.

[11]  Richard A. Adams,et al.  Clinical development of new drug–radiotherapy combinations , 2016, Nature Reviews Clinical Oncology.

[12]  T. Greenhalgh,et al.  Combination of Novel Agents with Radiotherapy to Treat Rectal Cancer. , 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

[13]  C. Allegra,et al.  Neoadjuvant Rectal (NAR) Score: a New Surrogate Endpoint in Rectal Cancer Clinical Trials , 2015, Current Colorectal Cancer Reports.

[14]  T. Hothorn,et al.  Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. , 2015, The Lancet. Oncology.

[15]  T. DeWeese,et al.  Prospective randomized phase 2 trial of intensity modulated radiation therapy with or without oncolytic adenovirus-mediated cytotoxic gene therapy in intermediate-risk prostate cancer. , 2014, International journal of radiation oncology, biology, physics.

[16]  R. Weichselbaum,et al.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[17]  R. Weichselbaum,et al.  A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Kenneth J. Chang,et al.  EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study. , 2012, Gastrointestinal endoscopy.

[19]  R. Grossman,et al.  Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Stewart,et al.  Serotype-Specific Inactivation of the Cellular DNA Damage Response during Adenovirus Infection , 2010, Journal of Virology.

[21]  T. DeWeese,et al.  Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer , 2010, International journal of radiation biology.

[22]  Steve Thorne,et al.  Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer , 2008, PloS one.

[23]  Michael Branson,et al.  Critical aspects of the Bayesian approach to phase I cancer trials , 2008, Statistics in medicine.

[24]  Stephen L. Brown,et al.  Phase I trial of replication-competent adenovirus-mediated suicide gene therapy combined with IMRT for prostate cancer. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Laurence Collette,et al.  Chemotherapy with preoperative radiotherapy in rectal cancer. , 2006, The New England journal of medicine.

[26]  P. Fisher,et al.  Ionizing radiation enhances adenoviral vector expressing mda‐7/IL‐24‐mediated apoptosis in human ovarian cancer , 2006, Journal of cellular physiology.

[27]  J. Bell,et al.  Recent progress in the battle between oncolytic viruses and tumours , 2005, Nature Reviews Cancer.

[28]  E. B. Butler,et al.  Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. , 2005, International journal of radiation oncology, biology, physics.

[29]  P. Working,et al.  Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity , 2005, Cancer Gene Therapy.

[30]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[31]  R. Weichselbaum,et al.  A Phase I Trial of TNFerade Biologic in Patients with Soft Tissue Sarcoma in the Extremities , 2004, Clinical Cancer Research.

[32]  J. Zalcberg,et al.  A phase I trial of preoperative radiotherapy and capecitabine for locally advanced, potentially resectable rectal cancer , 2004, British Journal of Cancer.

[33]  K. Ulbrich,et al.  Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus , 2004, Gene Therapy.

[34]  R. Weichselbaum,et al.  TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  P. Opolon,et al.  Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts , 2003, British Journal of Cancer.

[36]  J. Dawson,et al.  Radiation increases the activity of oncolytic adenovirus cancer gene therapy vectors that overexpress the ADP (E3-11.6K) protein , 2003, Cancer Gene Therapy.

[37]  J. Bell,et al.  Oncolytic viruses: programmable tumour hunters. , 2002, Current gene therapy.

[38]  T. DeWeese,et al.  CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. , 2001, Cancer research.

[39]  J. Roth,et al.  Adenovirus-mediated wild-type p53 gene expression radiosensitizes non-small cell lung cancer cells but not normal lung fibroblasts , 2001, International journal of radiation biology.

[40]  Y K Cheung,et al.  Sequential Designs for Phase I Clinical Trials with Late‐Onset Toxicities , 2000, Biometrics.

[41]  M. Teo,et al.  Phase 2 Neoadjuvant Treatment Intensification Trials in Rectal Cancer: A Systematic Review. , 2018, International journal of radiation oncology, biology, physics.

[42]  D. Buchsbaum,et al.  Cancer Treatment with Gene Therapy and Radiation Therapy , 2013 .

[43]  D. Buchsbaum,et al.  Chapter seven--Cancer treatment with gene therapy and radiation therapy. , 2012, Advances in cancer research.

[44]  J. Gu,et al.  Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.